Table 1.

Evaluation of BAFF, S100, and PD-L1 as biomarkers of response to anti-PD1 therapy.

Response according to best overall responsea: individual biomarker
BAFF			S100			PD-L1
	R	NR		R	NR		R	NR
Low < 500 pg/mL	24	7	Low < 0.2 μg/L	13	4	Low < 10%	19	10
High ≥ 500 pg/mL	4	9	High ≥ 0.2 μg/L	10	10	High ≥ 10%	3	1
Fisher P	0.0058		Fisher P	0.1734		Fisher P	1
PPV	0.56		PPV	0.71		PPV	0.09
NPV	0.86		NPV	0.57		NPV	0.86
LR	3.07		LR	2.13		LR	0.73

Response according to best overall response: combined biomarkers
BAFF + PD-L1			BAFF + S100			BAFF + S100+ PD-L1
	R	NR		R	NR		R	NR
Low	22	11	Low	21	8	Low	25	9
Highb	0	0	Highb	2	6	Highc	3	7
Fisher P	1		Fisher P	0.0345		Fisher P	0.0225
PPV	0		PPV	0.43		PPV	0.44
NPV	1		NPV	0.91		NPV	0.89
LR			LR	2.72		LR	2.64

Abbreviations: NPV, negative predictive value; NR, no response [progressive disease (PD), death or MR with progression to new organ sites]; PPV, positive predictive value; R, response [complete remission (CR), partial response (PR), stable disease (SD), and mixed response (MR) with no involvement of new organ sites].

^aBest overall response is dependent on progress of disease after multiple courses of treatment, three staging and radiological analysis.

^bElevated BAFF and other biomarker elevated.

^cAny two or more biomarkers elevated.